Linked Data API

Show Search Form

Search Results

1055116
star this property registered interest false more like this
star this property date less than 2019-02-05more like thismore than 2019-02-05
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Obesity more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what support and assistance they plan to offer obese people with a body mass index of 30 and above who have not been diagnosed with Type 2 diabetes or hypertension. more like this
star this property tabling member printed
Lord Brooke of Alverthorpe more like this
star this property uin HL13442 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-02-19more like thismore than 2019-02-19
star this property answer text <p>Public Health England (PHE) has a responsibility to support the local delivery of evidence-based, effective and sustainable weight management services, as recommended by the National Institute for Health and Care Excellence (NICE), which support adults who are obese (that is, with a body mass index over 30 kg/m2, or lower for those from black and minority ethnic groups) or with other risk factors.</p><p>PHE provides practitioners, commissioners and providers of tier 2 weight management services with a range of resources to support the commissioning and delivery of these services. This includes:</p><p>- Guidance on how services should include diet, physical activity, and behaviour change components; and</p><p>- A tool to support the implementation of evidence-based behaviour change techniques.</p><p>A copy of this tool, <em>Changing Behaviour: Techniques for Tier 2 Adult Weight Management Services</em>, is attached.</p><p>NICE has also produced a guideline, <em>Weight management: lifestyle services for overweight or obese adults, </em>aimed at commissioners, health professionals, providers of lifestyle weight management programmes, adults who are overweight or obese, their families and other members of the public. This guideline covers lifestyle weight management services including programmes, courses, clubs or groups provided by the public, private and voluntary sector. The aim is to help people lose weight and become more physically active to reduce the risk of diseases associated with obesity. A copy of NICE’s guideline is attached.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property attachment
1
star this property file name changing behaviour techniques for tier 2 adult weight management services.pdf more like this
unstar this property title HL13442 attached document more like this
2
star this property file name weight-management-lifestyle-services-for-overweight-or-obese-adults-pdf-1996416726469.pdf more like this
unstar this property title HL13442 attached document more like this
star this property question first answered
less than 2019-02-19T14:09:01.71Zmore like thismore than 2019-02-19T14:09:01.71Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
3335
star this property label Biography information for Lord Brooke of Alverthorpe more like this
892406
star this property registered interest false more like this
star this property date less than 2018-04-26more like thismore than 2018-04-26
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Surgical Mesh Implants more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what action they are taking to prevent mesh from being offered routinely to patients as a first intervention. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL7313 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-05-09more like thismore than 2018-05-09
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) has published eight pieces of interventional procedures guidance that make a number of different recommendations about the safety and efficacy of various procedures using mesh to treat stress urinary incontinence or pelvic organ prolapse. They also emphasise the importance of informed consent and data collection, along with the requirement to report adverse events and the need for special training to undertake these procedures.</p><p>The most recent update was an update of its <em>Transvaginal mesh repair of anterior or posterior vaginal wall prolapse</em> interventional procedures guidance published on 15 December 2017. NICE recommends that this procedure should only be used in the context of research. The updated NICE recommendation does not constitute a “ban”, but specifies that research should include details of patient selection, long-term outcomes including complications, type of mesh used and method of fixation, and quality of life. A copy of the guidance is attached.</p><p>Additionally, NICE is extending its clinical guideline on the management of urinary incontinence in women to also include pelvic organ prolapse. The final guideline is expected to be published in 2019.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-05-09T11:34:22.893Zmore like thismore than 2018-05-09T11:34:22.893Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property attachment
1
star this property file name transvaginal-mesh-repair-of-anterior-or-posterior-vaginal-wall-prolapse-pdf.pdf more like this
unstar this property title NICE guidance transvaginal mesh repair more like this
star this property tabling member
2024
star this property label Biography information for Lord Hunt of Kings Heath more like this
988900
star this property registered interest false more like this
star this property date less than 2018-10-16more like thismore than 2018-10-16
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading General Practitioners: Liverpool more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what the ratio of GPs to patients was in each Liverpool parliamentary constituency in each of the past 10 years. more like this
star this property tabling member constituency Liverpool, Wavertree more like this
star this property tabling member printed
Luciana Berger more like this
star this property uin 180171 more like this
star this property answer
answer
unstar this property is ministerial correction true more like this
star this property date of answer less than 2018-10-22more like thismore than 2018-10-22
star this property answer text <p>The ratio of patients per general practitioner is provided in the table attached. Figures are not available at a parliamentary constituency level; therefore figures have been included at the lowest available level corresponding to these areas, specifically primary care trusts prior to 2013, and clinical commissioning groups from 2013 onwards.</p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-10-22T16:19:20.473Zmore like thismore than 2018-10-22T16:19:20.473Z
star this property question first ministerially corrected
less than 2018-10-23T09:15:31.057Zmore like thismore than 2018-10-23T09:15:31.057Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property attachment
1
star this property file name table PQ180171.docx more like this
unstar this property title GP to patient ratio more like this
star this property previous answer version
79964
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4036
star this property label Biography information for Luciana Berger more like this
917772
star this property registered interest false more like this
star this property date less than 2018-06-05more like thismore than 2018-06-05
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Mental Health Services more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government whether they intend to introduce a system for reporting adverse reactions to psychiatric and psychological treatments similar to the Yellow Card Scheme for medicines; and if not, why not. more like this
star this property tabling member printed
The Countess of Mar more like this
star this property uin HL8366 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-06-19more like thismore than 2018-06-19
star this property answer text <p>There are no current plans to introduce a separate scheme for reporting adverse reactions to psychiatric and psychological treatments. The Yellow Card Scheme already includes a facility to report suspected adverse incidents associated with products used in psychiatric and psychological treatments.</p><p>The National Institute for Health and Care Excellence (NICE) produces guidance for the National Health Service on how to treat certain health conditions, including mental health conditions and NICE clinical guidelines provide advice on the care and support that should be offered to people who use health and care services, including some therapeutic interventions for mental health. NICE guidance is based on a thorough assessment of the available evidence and is developed through extensive engagement with stakeholders. NHS organisations are expected to take it fully into account in the design of services to meet the needs of their populations.</p><p>NICE’s Quality Standard 14 - <em>Service user experience in adult mental health services </em>states that service providers should ensure systems are in place to collect feedback on the experience of care from service users and their families or carers. A copy of the Quality Standard is attached.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-06-19T16:18:34.34Zmore like thismore than 2018-06-19T16:18:34.34Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property attachment
1
star this property file name service-user-experience-in-adult-mental-health-services-pdf-2098485311173.pdf more like this
unstar this property title Service user experience in adult mental health more like this
star this property tabling member
1861
star this property label Biography information for The Countess of Mar more like this
1061379
star this property registered interest false more like this
star this property date less than 2019-02-14more like thismore than 2019-02-14
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Food: Safety more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what research they have carried out on the food safety effects of chlorine washing of (1) salad, and (2) meat, products. more like this
star this property tabling member printed
Lord Rooker more like this
star this property uin HL13759 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-02-28more like thismore than 2019-02-28
star this property answer text <p>The Food Standards Agency (FSA) advises that chlorine washes can be used on fresh produce, including salad, but are legally not permitted on products of animal origin or meat.</p><p> </p><p>Past research commissioned by the FSA includes <em>Reducing Campylobacter cross-contamination during poultry processing</em>. The researchers tested some substances, including, chlorine dioxide, and compared their effect with steam treatment. The results indicated that none of the treatments eliminated Campylobacter entirely. The FSA is continuing to review the literature and monitor the latest developments on the topic. A copy of the report is attached.</p> more like this
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property question first answered
less than 2019-02-28T15:20:54.217Zmore like thismore than 2019-02-28T15:20:54.217Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property attachment
1
star this property file name reducing-campylobacter-cross-contamination-during-poultry-processing.pdf more like this
unstar this property title Reducing Campylobacter cross contamination more like this
star this property tabling member
302
star this property label Biography information for Lord Rooker more like this
857590
star this property registered interest false more like this
star this property date less than 2018-03-07more like thismore than 2018-03-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Vitamin D more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of the impact of lack of access to prescription-based vitamin D on the long-term bone health of people who have low, or no, exposure to the sun. more like this
star this property tabling member printed
Baroness Masham of Ilton more like this
star this property uin HL6162 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-03-21more like thismore than 2018-03-21
star this property answer text <p>As part of the NHS England consultation <em>Conditions for which over the counter items should not routinely be prescribed in primary care: A consultation on guidance for CCGs</em>, NHS England has published a full Equality and Health Inequalities Impact Assessment, <em>Equality and Health Inequalities – Full Analysis Form – Conditions for which over the counter items should not routinely be prescribed in primary care,</em> which covers groups protected by the Equality Act 2010. Copies of both documents are attached.</p><p>In the summer months most people should be able to get all the vitamin D they need from sunlight on the skin. However, it is also found in some foods – oily fish, red meat, liver, egg yolks and fortified foods, such as most fat spreads and some breakfast cereals.</p><p>The Advisory Committee on Borderline Substances states that vitamins and minerals should be prescribed only in the management of actual or potential vitamin or mineral deficiency, and are not to be prescribed as dietary supplements. We understand that NHS England’s current consultation is in line with this. Prescribing vitamin D for maintenance would be classed as a treatment for prevention or as a dietary supplement.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property attachment
1
star this property file name otc-guidance-2.pdf more like this
unstar this property title OTC Guidance more like this
2
star this property file name Equality and Health Inequalities Impact Assessment.pdf more like this
unstar this property title Equality and Health Inequalities Impact Assessment more like this
star this property question first answered
less than 2018-03-21T15:43:36.213Zmore like thismore than 2018-03-21T15:43:36.213Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
1850
star this property label Biography information for Baroness Masham of Ilton more like this
985057
star this property registered interest false more like this
star this property date less than 2018-10-10more like thismore than 2018-10-10
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Spinal Muscular Atrophy: Drugs more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what guidance is provided to NHS Trusts about the use of medication not approved by NICE to treat spinal muscular atrophy (SMA). more like this
star this property tabling member printed
Viscount Waverley more like this
star this property uin HL10600 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-10-17more like thismore than 2018-10-17
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of nusinersen (Spinraza) for the treatment of spinal muscular atrophy (SMA).</p><p>NHS England has published an Interim Policy Statement <em>Urgent Clinical Commissioning Policy Statement: Nusinersen for genetically confirmed Spinal Muscular Atrophy (SMA) type 1 for eligible patients under the Expanded Access Programme (EAP) </em>determining the circumstances in which patients will be supported to access nusinersen through the EAP scheme sponsored by Biogen, the manufacturer of nusinersen. A copy is attached. The policy statement enables patients with type 1 SMA to access nusinersen in advance of NICE’s guidance.</p><p>In the absence of final guidance from NICE, clinicians can apply to NHS England for funding in exceptional cases through the individual funding request process.</p> more like this
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL10601 more like this
HL10602 more like this
star this property question first answered
less than 2018-10-17T15:08:15.027Zmore like thismore than 2018-10-17T15:08:15.027Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property attachment
1
star this property file name nusinersen-for-genetically-confirmed-spinal-muscular-atrophy.pdf more like this
unstar this property title Commissioning policy statement nusinersen more like this
star this property tabling member
1744
star this property label Biography information for Viscount Waverley more like this
985058
star this property registered interest false more like this
star this property date less than 2018-10-10more like thismore than 2018-10-10
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Spinal Muscular Atrophy: Drugs more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of making financial resources available to patients with spinal muscular atrophy (SMA) to obtain medication not approved by NICE. more like this
star this property tabling member printed
Viscount Waverley more like this
star this property uin HL10601 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-10-17more like thismore than 2018-10-17
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of nusinersen (Spinraza) for the treatment of spinal muscular atrophy (SMA).</p><p>NHS England has published an Interim Policy Statement <em>Urgent Clinical Commissioning Policy Statement: Nusinersen for genetically confirmed Spinal Muscular Atrophy (SMA) type 1 for eligible patients under the Expanded Access Programme (EAP) </em>determining the circumstances in which patients will be supported to access nusinersen through the EAP scheme sponsored by Biogen, the manufacturer of nusinersen. A copy is attached. The policy statement enables patients with type 1 SMA to access nusinersen in advance of NICE’s guidance.</p><p>In the absence of final guidance from NICE, clinicians can apply to NHS England for funding in exceptional cases through the individual funding request process.</p> more like this
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL10600 more like this
HL10602 more like this
star this property question first answered
less than 2018-10-17T15:08:15.097Zmore like thismore than 2018-10-17T15:08:15.097Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property attachment
1
star this property file name nusinersen-for-genetically-confirmed-spinal-muscular-atrophy.pdf more like this
unstar this property title Commissioning policy statement nusinersen more like this
star this property tabling member
1744
star this property label Biography information for Viscount Waverley more like this
985059
star this property registered interest false more like this
star this property date less than 2018-10-10more like thismore than 2018-10-10
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Spinal Muscular Atrophy: Nusinersen more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what guidance is provided by NHS Trusts about making the drug Spinraza available through the NHS to patients with spinal muscular atrophy (SMA). more like this
star this property tabling member printed
Viscount Waverley more like this
star this property uin HL10602 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-10-17more like thismore than 2018-10-17
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of nusinersen (Spinraza) for the treatment of spinal muscular atrophy (SMA).</p><p>NHS England has published an Interim Policy Statement <em>Urgent Clinical Commissioning Policy Statement: Nusinersen for genetically confirmed Spinal Muscular Atrophy (SMA) type 1 for eligible patients under the Expanded Access Programme (EAP) </em>determining the circumstances in which patients will be supported to access nusinersen through the EAP scheme sponsored by Biogen, the manufacturer of nusinersen. A copy is attached. The policy statement enables patients with type 1 SMA to access nusinersen in advance of NICE’s guidance.</p><p>In the absence of final guidance from NICE, clinicians can apply to NHS England for funding in exceptional cases through the individual funding request process.</p> more like this
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL10600 more like this
HL10601 more like this
star this property question first answered
less than 2018-10-17T15:08:15.16Zmore like thismore than 2018-10-17T15:08:15.16Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property attachment
1
star this property file name nusinersen-for-genetically-confirmed-spinal-muscular-atrophy.pdf more like this
unstar this property title Commissioning policy statement nusinersen more like this
star this property tabling member
1744
star this property label Biography information for Viscount Waverley more like this
909644
star this property registered interest false more like this
star this property date less than 2018-05-22more like thismore than 2018-05-22
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Hepatitis: Prisoners more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what plans they have to ensure that all new prisoners are offered a test for hepatitis C and have rapid access to care. more like this
star this property tabling member printed
Baroness Masham of Ilton more like this
star this property uin HL8139 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-06-05more like thismore than 2018-06-05
star this property answer text <p>Public Health England, Her Majesty’s Prison and Probation Service and NHS England introduced ‘opt-out’ testing for blood-borne viruses, including hepatitis C, in prisons in the first National Partnership Agreement published in 2013 with phased implementation through a series of pathfinder prisons in three successive phases. Full implementation across the whole adult prison estate in England was concluded in financial year 2017/18, as described in the 2015 Second National Partnership Agreement. A copy of the <em>National Partnership Agreement between: The National Offender Management Service, NHS England and Public Health England for the Co-Commissioning and Delivery of Healthcare Services in Prisons in England 2015-2016</em> is attached.</p><p>All new consenting eligible adult receptions to prisons in England are now offered a hepatitis C test on an opt-out basis within 72 hours of reception in accordance with published national guidance; this usually occurs at second reception health screening. The standard for patients testing positive for hepatitis C is referral to specialists for assessment within a maximum of 18 weeks from referral.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-06-05T16:05:41.83Zmore like thismore than 2018-06-05T16:05:41.83Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property attachment
1
star this property file name national_partnership_agreement_commissioning-delivery-healthcare-prisons_2015.pdf more like this
unstar this property title National Partnership Agreement 2015-16 more like this
star this property tabling member
1850
star this property label Biography information for Baroness Masham of Ilton more like this